Corynebacterium dephtherae Vaccines
Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against diphtheria caused by Corynebacterium dephtherae and guarantee the finest results for our customers all over the world.
Corynebacterium diphtheria (C. diphtheria) is a non-motile, non-encapsulated, non-sporulating gram-positive rod-shaped bacterium with a high GC-content and occurs in four biovars: gravis, mitis, intermedius, and belfanti, based on colonial morphology and biochemical profiles. It is the causal agent of the disease diphtheria which is an upper respiratory tract illness characterized by sore throat, low fever, and an adherent membrane on the tonsils, pharynx, and/or nasal cavity. Diphtheria is a contagious disease transmitted between humans via droplets, secretions or direct contact with fatality rates between 5% and 10%. For children under 5 years and adults over 40 years, the fatality rate may be as much as 20%.
Combination Vaccines
The diphtheria vaccine is mainly combined with other vaccines, so a person can receive protection from several diseases with one shot. There are several kinds of vaccines available to protect against diphtheria. The development of combination vaccines for protection against multiple diseases containing diphtheria began with the combination of individual diphtheria, tetanus, and pertussis (DTP) vaccines into a single product. Therefore, DTP has become the cornerstone of pediatric and adult immunization programs and other vaccines are subsequently added to the combination and replacement components to improve its reactogenicity profile. There is an important advancement that is the replacement of whole-cell pertussis antigens (wP) with less reactogenic acellular antigens (aP). This paved the way for the combination of DTaP with other routine vaccines such as inactivated polio vaccine (IPV), Haemophilus influenzae vaccine (Hib), and hepatitis B vaccine (HepB).
In addition to combination vaccines that are routinely available, such as DT (diphtheria and tetanus) vaccines, DTaP (diphtheria, tetanus, and pertussis) vaccines, Td (tetanus and diphtheria) vaccines, there are several other combinations based on DTaP. DTaP-HepB-Hib/IPV protects against six different diseases. It is composed of diphtheria, tetanus, and acellular pertussis antigens, hepatitis B surface antigen, inactivated poliovirus, and Haemophilus influenzae polyribosylribitol phosphate antigen conjugated to tetanus toxoid. It is adjuvanted with both aluminum hydroxide and aluminum phosphate adjuvants, which is due to the combination of DTaP vaccine adsorbed onto aluminum hydroxide and HepB vaccine adsorbed onto aluminum phosphate. Besides, DTaP-IPV-Hib (diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b) and DTaP-IPV (tetanus, diphtheria, pertussis, and polio) also protect people against the diseases which are serious and sometimes fatal. These combination vaccines are much safer to get immunized than to get these diseases and can make the immune system stronger by building antibodies which help prevent diseases.
Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against diphtheria caused by Corynebacterium dephtherae. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
